NCT05535959View on ClinicalTrials.gov

A Study to Evaluate the Relative Bioavailability of a Fixed-dose Combination Tablet of VX-121/Tezacaftor/Deutivacaftor

PHASE1CompletedINTERVENTIONAL

Enrollment

16

Participants

Timeline

Start Date

September 15, 2022

Primary Completion Date

November 9, 2022

Study Completion Date

November 9, 2022

Conditions

Cystic Fibrosis

Interventions

DRUG

VX-121/TEZ/D-IVA

FDC tablet for oral administration.

Trial Locations (1)

84124

ICON Salt Lake City, Salt Lake City

All Listed Sponsors

lead

Vertex Pharmaceuticals Incorporated

INDUSTRY